To further validate the tumour‐targeting performance of 89Zr‐labelled CD19 CAR T on CD19‐positive tumour in vivo, micro‐PET imaging was performed in the CD19‐positive group and CD19‐negative group. The gene discussed is CD19; the disease is neoplasm.